Biomednewsbreaks - Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results At ECTRIMS 2025

(MENAFN- Investor Brand Network) Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive MS patients. Treatment also produced significant changes in brain NAD+ and NADH fractions, with correlations between baseline brain energy metabolism and disability, cognition, and motor function. CNM-Au8 was safe and well tolerated, reinforcing its potential to slow disease progression by addressing bioenergetic failure in MS.

To view the full press release, visit

About Clene Inc.

Clene Inc., (NASDAQ: CLNN) (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on X (formerly Twitter) and LinkedIn .

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN25092025000224011066ID1110111908